Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Market Cap	27.07B
Revenue (ttm)	1.57B
Net Income (ttm)	568.30M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	47.63
Forward PE	42.60
Dividend	0.04 (0.91%)
Ex-Dividend Date	Sep 22, 2025

Volume	n/a
Average Volume	556
Open	4.420
Previous Close	4.460
Day's Range	4.420 - 4.420
52-Week Range	1.970 - 4.460
Beta	n/a
RSI	63.39
Earnings Date	Nov 17, 2025

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3KY

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY